IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 69.26

Change

+0.16 (+0.23)%

Market Cap

N/A

Volume

0.07M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-29 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.86 (-0.59%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

-0.36 (-0.52%)

USD 2.66B
FXH First Trust Health Care AlphaD..

-0.12 (-0.11%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

-0.27 (-0.28%)

USD 0.21B
IDNA iShares Genomics Immunology an..

-0.17 (-0.75%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.25 (+0.76%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-0.41 (-0.40%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

-0.40 (-1.29%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.38 (-0.61%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.05 (-0.21%)

USD 6.89M

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.39% 35% F 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.39% 35% F 80% B-
Trailing 12 Months  
Capital Gain 8.86% 67% D+ 56% F
Dividend Return 1.46% 94% A 24% F
Total Return 10.32% 71% C- 50% F
Trailing 5 Years  
Capital Gain 30.49% 48% F 63% D
Dividend Return 8.92% 95% A 26% F
Total Return 39.41% 52% F 59% D-
Average Annual (5 Year Horizon)  
Capital Gain 4.22% 48% F 48% F
Dividend Return 5.61% 57% F 45% F
Total Return 1.39% 100% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 15.37% 71% C- 66% D+
Risk Adjusted Return 36.50% 67% D+ 50% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike